{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T07:06:49Z","timestamp":1781248009100,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773558"],"award-info":[{"award-number":["81773558"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073689"],"award-info":[{"award-number":["82073689"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018B030312010"],"award-info":[{"award-number":["2018B030312010"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A151501518"],"award-info":[{"award-number":["2020A151501518"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004000","name":"Guangzhou Science and Technology Program key projects","doi-asserted-by":"publisher","award":["201904010380"],"award-info":[{"award-number":["201904010380"]}],"id":[{"id":"10.13039\/501100004000","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.bmc.2023.117261","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T04:50:38Z","timestamp":1680151838000},"page":"117261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3K\u03b3 antagonist"],"prefix":"10.1016","volume":"84","author":[{"given":"Yuqing","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahua","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bmc.2023.117261_b0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol."},{"issue":"1","key":"10.1016\/j.bmc.2023.117261_b0010","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun."},{"issue":"1","key":"10.1016\/j.bmc.2023.117261_b0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","article-title":"Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape","volume":"7","author":"Osipov","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"26","key":"10.1016\/j.bmc.2023.117261_b0020","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.bmc.2023.117261_b0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.1800991","article-title":"The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves","volume":"202","author":"Kerr","year":"2019","journal-title":"J Immunol."},{"issue":"11","key":"10.1016\/j.bmc.2023.117261_b0030","doi-asserted-by":"crossref","first-page":"7371","DOI":"10.1021\/acs.jmedchem.0c02266","article-title":"Design, Synthesis, and Structure-Activity Relationship of N-Aryl-N'-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1\/2 Agonists for Potential Cancer Immunotherapy","volume":"64","author":"Chen","year":"2021","journal-title":"J Med Chem."},{"issue":"10","key":"10.1016\/j.bmc.2023.117261_b0035","doi-asserted-by":"crossref","first-page":"1802042","DOI":"10.1002\/advs.201802042","article-title":"TLR1\/2 Specific Small-Molecule Agonist Suppresses Leukemia Cancer Cell Growth by Stimulating Cytotoxic T Lymphocytes","volume":"6","author":"Cen","year":"2019","journal-title":"Adv Sci."},{"key":"10.1016\/j.bmc.2023.117261_b0040","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2019.02.067","article-title":"Synthesis of urea analogues bearing N-alkyl-N'-(thiophen-2-yl) scaffold and evaluation of their innate immune response to toll-like receptors","volume":"169","author":"Chen","year":"2019","journal-title":"Eur J Med Chem."},{"issue":"4","key":"10.1016\/j.bmc.2023.117261_b0045","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K Pathway in Human Disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"issue":"41","key":"10.1016\/j.bmc.2023.117261_b0050","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bmc.2023.117261_b0055","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0092-8674(00)00196-3","article-title":"Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma","volume":"103","author":"Pacold","year":"2000","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.bmc.2023.117261_b0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.bmc.2023.117261_b0065","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1182\/blood-2005-03-0944","article-title":"Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils","volume":"106","author":"Condliffe","year":"2005","journal-title":"Blood"},{"issue":"7505","key":"10.1016\/j.bmc.2023.117261_b0070","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nature13444","article-title":"Inactivation of PI(3)K p110\u03b4 breaks regulatory T-cell-mediated immune tolerance to cancer","volume":"510","author":"Ali","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.bmc.2023.117261_b0075","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1021\/acsmedchemlett.6b00238","article-title":"Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-\u03b3 Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate","volume":"7","author":"Evans","year":"2016","journal-title":"ACS Med Chem Lett"},{"issue":"7629","key":"10.1016\/j.bmc.2023.117261_b0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"issue":"Pt 1","key":"10.1016\/j.bmc.2023.117261_b0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/bst0310275","article-title":"Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy","volume":"31","author":"Wymann","year":"2003","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.bmc.2023.117261_b0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/nyas.12037","article-title":"Inhibition of phosphoinositide 3-kinase \u03b3 attenuates inflammation, obesity, and cardiovascular risk factors","volume":"1280","author":"Wymann","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bmc.2023.117261_b0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pharmthera.2014.09.006","article-title":"Targeting PI3 kinase in cancer","volume":"146","author":"Bauer","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.bmc.2023.117261_b0100","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/2159-8290.CD-16-0716","article-title":"Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy","volume":"6","author":"Okkenhaug","year":"2016","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.bmc.2023.117261_b0105","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem Biol"},{"issue":"13","key":"10.1016\/j.bmc.2023.117261_b0110","doi-asserted-by":"crossref","first-page":"8439","DOI":"10.1074\/jbc.M114.634683","article-title":"Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase \u03b4","volume":"290","author":"Somoza","year":"2015","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.bmc.2023.117261_b0115","doi-asserted-by":"crossref","first-page":"11235","DOI":"10.1021\/acs.jmedchem.0c01203","article-title":"Discovery of Potent and Selective PI3K\u03b3 Inhibitors","volume":"63","author":"Drew","year":"2020","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623001098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623001098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:22:09Z","timestamp":1760836929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089623001098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":23,"alternative-id":["S0968089623001098"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117261","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3K\u03b3 antagonist","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117261"}}